Study shows H1N1 microneedle vaccine protects better than injection

Vaccine delivered to the skin of mice using a microneedle patch provides better protection against H1N1 influenza virus than a vaccine delivered through injection, researchers have found. (Georgia Tech Photo: Gary Meek)

(Medical Xpress) -- A vaccine delivered to the skin using a microneedle patch gives better protection against the H1N1 influenza virus than a vaccine delivered through subcutaneous or intramuscular injection, researchers from Emory University and the Georgia Institute of Technology have found. Their research is published online in the Journal of Infectious Diseases.

Mice given a single H1N1 vaccine through the skin using a coated metal microneedle patch as well as mice vaccinated through subcutaneous injection were 100 percent protected against a lethal challenge six weeks after vaccination. However, when challenged with the H1N1 virus six months later, the injected mice had a 60 percent decrease in antibody production against the virus and extensive lung inflammation. Mice that were vaccinated with microneedles, on the other hand, maintained high levels of protection and after six months, with no signs of .

"A major goal of development has been to confer strong immune responses, including immunological memory and cellular immune responses for long-term protection, and to limit virus spread after infection," said first author Dimitrios Koutsonanos, MD, post-doctoral fellow of microbiology and immunology at Emory University School of Medicine.

The research team also included Ioanna Skountzou, MD, PhD, Richard Compans, PhD, Maria del Pilar Martin, PhD, and Joshy Jacob, PhD, from Emory, and Georgia Tech bioengineers Mark Prausnitz, PhD, and Vladimir Zarnitsyn, PhD.

Researchers already have found that intramuscular injection is not the most efficient way to deliver vaccines. The muscles have a low concentration of cells needed to relay immune signals and activate a T-cell response, including , macrophages, and MHC class II-expressing cells. The skin, however, contains a rich network of antigen-presenting cells, including macrophages, Langerhans cells and dermal dendritic cells that activate cytokines and chemokines – immune signaling cells responsible for initiating an immune response.

The Emory/Georgia Tech research team previously reported that delivery of seasonal influenza vaccine through the skin using antigen-coated metal microneedle patches or dissolving elicited strong immune responses that can confer protection at least equal to conventional intramuscular injections. The team has developed dissolving microneedle technology that could be used in easy-to-administer, painless patches.

"The pandemic H1N1 A/California/04/09 continues to be the predominant strain," said lead researcher Ioanna Skountzou, MD, PhD, assistant professor of microbiology and immunology at Emory University School of Medicine. "Our research shows that skin-based vaccination, made possible through microneedle technology, may now be a viable and more effective alternative to intramuscular injection for H1N1 flu and other strains as well."

"Microneedle delivery also offers other logistical advantages that make this method attractive for influenza vaccination, such as inexpensive manufacturing, small size for easy storage and distribution, and simple administration that might enable self-vaccination to increase patient coverage," said Prausnitz.

Related Stories

Tattooing improves response to DNA vaccine

Feb 07, 2008

A tattoo can be more than just a fashion statement – it has potential medical value, according to an article published in the online open access journal, Genetic Vaccines and Therapy.

2009 H1N1 vaccine protects against 1918 influenza virus

Jun 15, 2010

Researchers at Mount Sinai School of Medicine have determined people who were vaccinated against the 2009 H1N1 influenza virus may also be protected against the lethal 1918 Spanish influenza virus, which killed more than ...

Recommended for you

UN releases $1.5mn to help DR Congo fight Ebola

1 hour ago

The United Nations on Wednesday allocated $1.5 million (1.1 million euros) to help the Democratic Republic of Congo fight Ebola, just days after the country confirmed its first cases this year.

'Junk' blood tests may offer life-saving information

3 hours ago

Some 30 percent of all positive hospital blood culture samples are discarded every day because they're "contaminated"—they reflect the presence of skin germs instead of specific disease-causing bacteria.

Drug represents first potential treatment for common anemia

3 hours ago

An experimental drug designed to help regulate the blood's iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment published online today in Blood, the Journal of the American Society o ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

that_guy
not rated yet Jul 12, 2011
and ummm...it'll make it a little easier to vaccinate kids.